41 related articles for article (PubMed ID: 28108506)
1. Markers of B-cell activation in relation to risk of non-Hodgkin lymphoma.
De Roos AJ; Mirick DK; Edlefsen KL; LaCroix AZ; Kopecky KJ; Madeleine MM; Magpantay L; Martínez-Maza O
Cancer Res; 2012 Sep; 72(18):4733-43. PubMed ID: 22846913
[TBL] [Abstract][Full Text] [Related]
2. Cancer Biomarkers V: Update on B-Cell Lymphoma Biomarkers.
Crane GM
Arch Pathol Lab Med; 2024 May; 148(5):e90-e95. PubMed ID: 37776258
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal Changes in Immune Activation Serum Biomarkers Prior to Diagnosis and Risk of B-cell NHL Subtypes.
Levin LI; Ramirez CM; Liao EL; Guo H; Kim BK; Marrogi AJ; Magpantay LI; Breen EC; Martínez-Maza O
Cancer Epidemiol Biomarkers Prev; 2023 Feb; 32(2):233-241. PubMed ID: 36409490
[TBL] [Abstract][Full Text] [Related]
4. Circulating immune markers and risks of non-Hodgkin lymphoma subtypes: A pooled analysis.
Rhee J; Birmann BM; De Roos AJ; Epstein MM; Martinez-Maza O; Breen EC; Magpantay LI; Levin LI; Visvanathan K; Hosgood HD; Rohan TE; Smoller SW; Bassig BA; Qi L; Shu XO; Koh WP; Zheng W; Yuan JM; Weinstein SJ; Albanes D; Lan Q; Rothman N; Purdue MP
Int J Cancer; 2023 Mar; 152(5):865-878. PubMed ID: 36151863
[TBL] [Abstract][Full Text] [Related]
5. Pre-diagnostic levels of sVEGFR2, sTNFR2, sIL-2Rα and sIL-6R are associated with glioma risk: A nested case-control study of repeated samples.
Wu WY; Späth F; Wibom C; Björkblom B; Dahlin AM; Melin B
Cancer Med; 2022 Feb; 11(4):1016-1025. PubMed ID: 35029050
[TBL] [Abstract][Full Text] [Related]
6. Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma.
Lokhande L; Kuci Emruli V; Eskelund CW; Kolstad A; Hutchings M; Räty R; Niemann CU; Grønbaek K; Jerkeman M; Ek S
Cancer Rep (Hoboken); 2022 Jul; 5(7):e1524. PubMed ID: 34319003
[TBL] [Abstract][Full Text] [Related]
7. Genetic Variants in
Fu Z; Cai W; Shao J; Xue H; Ge Z; Fan H; Dong C; Wang C; Zhang J; Shen C; Zhang Y; Huang P; Yue M
Front Genet; 2021; 12():630310. PubMed ID: 33841497
[TBL] [Abstract][Full Text] [Related]
8. Circulating Biomarkers of Inflammation and Ovarian Cancer Risk in the Nurses' Health Studies.
Peres LC; Townsend MK; Birmann BM; Conejo-Garcia JR; Kim Y; Kubzansky LD; Magpantay LI; Martinez-Maza O; Tworoger SS
Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):710-718. PubMed ID: 33563649
[TBL] [Abstract][Full Text] [Related]
9. Immune marker changes and risk of multiple myeloma: a nested case-control study using repeated pre-diagnostic blood samples.
Späth F; Wibom C; Krop EJM; Santamaria AI; Johansson AS; Bergdahl IA; Hultdin J; Vermeulen R; Melin B
Haematologica; 2019 Dec; 104(12):2456-2464. PubMed ID: 30948485
[TBL] [Abstract][Full Text] [Related]
10. Circulating sCD27 and sCD30 in pre-diagnostic samples collected fifteen years apart and future non-Hodgkin lymphoma risk.
Purdue MP; Lan Q; Hoffman-Bolton J; Hildesheim A; Callahan CL; Strickland P; Visvanathan K; Rothman N
Int J Cancer; 2019 Apr; 144(8):1780-1785. PubMed ID: 30230539
[TBL] [Abstract][Full Text] [Related]
11. Evolving DNA methylation and gene expression markers of B-cell chronic lymphocytic leukemia are present in pre-diagnostic blood samples more than 10 years prior to diagnosis.
Georgiadis P; Liampa I; Hebels DG; Krauskopf J; Chatziioannou A; Valavanis I; de Kok TMCM; Kleinjans JCS; Bergdahl IA; Melin B; Spaeth F; Palli D; Vermeulen RCH; Vlaanderen J; Chadeau-Hyam M; Vineis P; Kyrtopoulos SA;
BMC Genomics; 2017 Sep; 18(1):728. PubMed ID: 28903739
[TBL] [Abstract][Full Text] [Related]
12. Biomarker Dynamics in B-cell Lymphoma: A Longitudinal Prospective Study of Plasma Samples Up to 25 Years before Diagnosis.
Späth F; Wibom C; Krop EJ; Johansson AS; Bergdahl IA; Vermeulen R; Melin B
Cancer Res; 2017 Mar; 77(6):1408-1415. PubMed ID: 28108506
[TBL] [Abstract][Full Text] [Related]
13. Soluble B-cell activation marker of sCD27 and sCD30 and future risk of B-cell lymphomas: A nested case-control study and meta-analyses.
Hosnijeh FS; Portengen L; Späth F; Bergdahl IA; Melin B; Mattiello A; Masala G; Sacerdote C; Naccarati A; Krogh V; Tumino R; Chadeau-Hyam M; Vineis P; Vermeulen R
Int J Cancer; 2016 May; 138(10):2357-67. PubMed ID: 26684261
[TBL] [Abstract][Full Text] [Related]
14. Prediagnostic serum sCD27 and sCD30 in serial samples and risks of non-Hodgkin lymphoma subtypes.
Purdue MP; Lan Q; Langseth H; Grimsrud TK; Hildesheim A; Rothman N
Int J Cancer; 2020 Jun; 146(12):3312-3319. PubMed ID: 31523805
[TBL] [Abstract][Full Text] [Related]
15. Mediating effect of soluble B-cell activation immune markers on the association between anthropometric and lifestyle factors and lymphoma development.
Saberi Hosnijeh F; Kolijn PM; Casabonne D; Nieters A; Solans M; Naudin S; Ferrari P; Mckay JD; Weiderpass E; Perduca V; Besson C; Mancini FR; Masala G; Krogh V; Ricceri F; Huerta JM; Petrova D; Sala N; Trichopoulou A; Karakatsani A; La Vecchia C; Kaaks R; Canzian F; Aune D; Boeing H; Schulze MB; Perez-Cornago A; Langerak AW; van der Velden VHJ; Vermeulen R
Sci Rep; 2020 Aug; 10(1):13814. PubMed ID: 32796953
[TBL] [Abstract][Full Text] [Related]
16. Markers of Immune Activation and Inflammation, and Non-Hodgkin Lymphoma: A Meta-Analysis of Prospective Studies.
Makgoeng SB; Bolanos RS; Jeon CY; Weiss RE; Arah OA; Breen EC; Martínez-Maza O; Hussain SK
JNCI Cancer Spectr; 2018 Dec; 2(4):pky082. PubMed ID: 30873511
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
